NZ Inflammatory Bowel Disease Research Review Issue 55

In this issue:
  -  BI 695501 biosimilar vs adalimumab in advanced CD
  -  Adalimumab biosimilar SB5 in IBD
  -  Etrolizumab for UC
  -  Etrolizumab as induction and maintenance therapy for UC (HICKORY)
  -  Etrolizumab for maintenance therapy in active UC (LAUREL)
  -  Etrolizumab vs infliximab for active UC (GARDENIA)
  -  Etrolizumab vs adalimumab or placebo as induction for UC (HIBISCUS I & II)
  -  Prediction of IBD course based on faecal volatile compounds
  -  Risk of dementia in patients with IBD
  -  Paradoxical psoriasis or psoriasiform lesions with anti-TNFs
  -  Patients’ and caregivers’ perspectives on biosimilar use in paediatric IBD
  -  Co-existent IBD and coeliac disease in children
  -  Science blog: Inflammation in colitis-associated cancer

Please login below to download this issue (PDF)

Subscribe